Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Retained Earnings (2016 - 2025)

iBio (IBIO) has disclosed Retained Earnings for 15 consecutive years, with -$346.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 7.68% to -$346.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$346.9 million, a 7.68% decrease, with the full-year FY2025 number at -$332.2 million, down 5.86% from a year prior.
  • Retained Earnings was -$346.9 million for Q4 2025 at iBio, down from -$337.9 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$63000.0 in Q2 2021 to a low of -$346.9 million in Q4 2025.
  • A 5-year average of -$210.5 million and a median of -$291.8 million in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: skyrocketed 99.96% in 2021, then plummeted 378118.75% in 2022.
  • iBio's Retained Earnings stood at -$194.5 million in 2021, then soared by 99.91% to -$167000.0 in 2022, then plummeted by 181275.45% to -$302.9 million in 2023, then fell by 6.37% to -$322.2 million in 2024, then dropped by 7.68% to -$346.9 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Retained Earnings are -$346.9 million (Q4 2025), -$337.9 million (Q3 2025), and -$332.2 million (Q2 2025).